Communication Insurance Coverage and Processing Presentation 
Putting Patients First Blog
SEPTEMBER 3, 2024
Other members include health-related associations and nonprofit organizations including the provider, research, and family caregiver communities; and businesses and organizations representing biopharmaceuticals, devices, diagnostics, generics, and payers.
Putting Patients First Blog
JANUARY 10, 2024
Making available more specific information about total costs and coverage will ensure that all consumers have comprehensive information to help them make smart health care decisions. These resources should aim to clarify insurance terms and concepts, aiding consumers in navigating the complexities of selecting a health plan.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
OCTOBER 7, 2021
Contact: Antonietta Pannella, Marketing & Communications Director, Healthware Group. “In some countries, such as Germany, France, and the United Kingdom, certain Digital Therapeutics are readily reimbursed and marketed. .
The Thyroid Pharmacist
AUGUST 4, 2023
In fact, it’s present in up to 55 percent of the European population, is naturally occurring, and often has no negative health consequences – unless expressed. [1] Unfortunately, synthetic folic acid can be highly problematic for individuals with the MTHFR gene variation, as they may have a difficult time processing this form of folate.
Proxsys Rx
SEPTEMBER 26, 2023
Even with her insurance coverage, the co-pay was beyond her means. If it had been a large chain pharmacy, she would have essentially been presented with the option of paying a bill she couldn’t afford — or doing without. Our pharmacists were only too happy to help.
Putting Patients First Blog
APRIL 29, 2024
The NHC commends CMS for its work in making these materials understandable – a vital component of beneficiary communication and education. While we find these documents generally well-constructed and accessible, there are opportunities for improvement to ensure they fully convey the MPPP’s intricacies to all beneficiaries.
European Pharmaceutical Review
MARCH 28, 2024
Measuring treatment effect in rare disease populations presents many methodological challenges due to small sample sizes and heterogeneity of the study population. When Aidan’s insurance company denied coverage for EXONDYS, the data she captured overturned the denial in 24 hours without engaging in the appeal process.
Expert insights. Personalized for you.
52 
Let's personalize your content